Tips and tricks based on a concise evaluation of <scp>TECHNOSCREEN</scp>® <scp>ADAMTS13</scp> activity assay before implementation as a screening tool for detecting deficiency of <scp>ADAMTS13</scp>

Cornette, Margot; Devreese, Katrien M. J.

doi:10.1111/ijlh.14175

Int J Lab Hematology

2023

DOI: 10.1111/ijlh.14175

|View full text |Cite

Tips and tricks based on a concise evaluation of TECHNOSCREEN® ADAMTS13 activity assay before implementation as a screening tool for detecting deficiency of ADAMTS13

Margot Cornette,

Katrien M. J. Devreese

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Real‐World Retrospective Audit on the Use of the TechnoClone TECHNOSCREEN ADAMTS‐13 Assay in the Diagnostic Process for Thrombotic Thrombocytopenic Purpura at LabPlus, New Zealand

Wong,

Thalari,

Ruskova

et al. 2024

Int J Lab Hematology

View full text Add to dashboard Cite

IntroductionThe TECHNOSCREEN ADAMTS‐13 assay (ADSC) is a new lateral flow test which is simple and quick to perform, with a high negative predictive value (NPV); it may improve the diagnostic workflow for TTP. LabPlus in Auckland, New Zealand, performs all ADAMTS13 tests in the Auckland and Northland regions. The ADSC was used at LabPlus between 2022 and 2023 as part of a protocol where results of 0 IU/mL and 0.1 IU/mL were confirmed with the TECHNOZYM ADAMTS‐13 Activity chromogenic ELISA assay (ADATS). The aim was to improve cost efficiency by reducing the need for the labour‐intensive ADATS, particularly in low probability requests. This retrospective audit analyses the efficacy and efficiency of the testing protocol.MethodsAll ADAMTS‐13 tests performed in the year before the ADSC (March 2021–March 2022) and after the ADSC protocol was introduced (March 2022–March 2023) were collected from the LabPlus laboratory information system (LIS), and correlated with clinical information from the electronic health record. Statistical analysis was performed.ResultsNinety‐four test requests were audited. ADSC had an NPV of 100% on diagnostic samples. The protocol increased the median turn‐around time (TAT) by 18 h (p = 0.01). If an ADSC of 0.1 IU/mL was taken as a negative, the median TAT was decreased by 17 h (p = 0.0003) in diagnostic samples from LabPlus adjacent hospitals.ConclusionADSC has a high NPV but did not improve TAT when used as part of a testing protocol for our central laboratory receiving samples from a large area.

show abstract

Real‐World Retrospective Audit on the Use of the TechnoClone TECHNOSCREEN ADAMTS‐13 Assay in the Diagnostic Process for Thrombotic Thrombocytopenic Purpura at LabPlus, New Zealand

Wong,

Thalari,

Ruskova

et al. 2024

Int J Lab Hematology

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Tips and tricks based on a concise evaluation of TECHNOSCREEN® ADAMTS13 activity assay before implementation as a screening tool for detecting deficiency of ADAMTS13

Cited by 1 publication

References 6 publications

Real‐World Retrospective Audit on the Use of the TechnoClone TECHNOSCREEN ADAMTS‐13 Assay in the Diagnostic Process for Thrombotic Thrombocytopenic Purpura at LabPlus, New Zealand

Real‐World Retrospective Audit on the Use of the TechnoClone TECHNOSCREEN ADAMTS‐13 Assay in the Diagnostic Process for Thrombotic Thrombocytopenic Purpura at LabPlus, New Zealand

Contact Info

Product

Resources

About